Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 88-94

  Advani, Ranjana H ^a   Buggy, Joseph J ^b   Sharman, Jeff P ^c   Smith, Sonali M ^d   Boyd, Thomas E ^e   Grant, Barbara ^g   Kolibaba, Kathryn S ^f   Furman, Richard R ^h   Rodriguez, Sara ^b   Chang, Betty Y ^b   Sukbuntherng, Juthamas ^b   Izumi, Raquel ^b   Hamdy, Ahmed ^b   Hedrick, Eric ^b   Fowler, Nathan H ⁱ  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b PHARMACYCLICS INC   (United States)

^c US Oncology   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Yakima Valley Memorial Hospital   (United States)

^f US Oncology   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB;

ADULT; AGED; ALLERGIC PNEUMONITIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSPEPSIA; EDEMA; ENZYME ACTIVE SITE; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SALVAGE THERAPY;

EID: 84871806385     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.7906     Document Type: Article

References (30)

1. Niiro H, Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2:945-956, 2002
2. Fuentes-Pananá EM, Bannish G, Monroe JG: Basal B-cell receptor signaling in B lymphocytes: Mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol Rev 197:26-40, 2004
3. Chiorazzi N, Ferrarini M: B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894, 2003
4. Stevenson FK, Caligaris-Cappio F: Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103:4389-4395, 2004
5. Küppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251-262, 2005
6. Gururajan M, Jennings CD, Bondada S: Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 176:5715-5719, 2006
7. Irish JM, Czerwinski DK, Nolan GP, et al: Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108:3135-3142, 2006
8. Pleyer L, Egle A, Hartmann TN, et al: Molecular and cellular mechanisms of CLL: Novel therapeutic approaches. Nat Rev Clin Oncol 6:405-418, 2009
9. Quiroga MP, Balakrishnan K, Kurtova AV, et al: B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 14:1029-1037, 2009
10. Lenz G, Staudt LM: Aggressive lymphomas. N Engl J Med 362:1417-1429, 2010
11. Cheng G, Ye ZS, Baltimore D: Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction. Proc Natl Acad Sci U S A 91:8152-8155, 1994
12. Afar DE, Park H, Howell BW, et al: Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol 16:3465-3471, 1996
13. Khan WN: Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 23:147-156, 2001
14. Humphries LA, Dangelmaier C, Sommer K, et al: Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase C gamma Src homology 2-Src homology 3 linker. J Biol Chem 279:37651-37661, 2004
15. Conley ME, Dobbs AK, Farmer DM, et al: Primary B cell immunodeficiencies: Comparisons and contrasts. Annu Rev Immunol 27:199-227, 2009
16. Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075-13080, 2010
17. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010
18. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
19. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520-525, 2009
22. Furman RR, Byrd JC, Flinn IW, et al: Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 28:241s, 2010 (suppl 15; abstr 3032)
23. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585, 2010
24. Ponader S, Chen S, Buggy JJ, et al: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182-1189, 2012
25. De Rooij MF, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590-2594, 2012
26. Chang BY, Francesco M, Magadala P, et al: Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor, PCI-32765, in mantle cell lymphoma patients. Blood 118, 2011 (abstr 954)
27. Anderson JS, Teutsch M, Dong Z, et al: An essential role for Bruton's tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci U S A 93:10966-10971, 1996
28. Rui L, Schmitz R, Ceribelli M, et al: Malignant pirates of the immune system. Nat Immunol 12:933-940, 2011
29. Kurosaki T, Shinohara H, Baba Y: B cell signaling and fate decision. Annu Rev Immunol 28:21-55, 2009
30. Herishanu Y, Pérez-Galán P, Liu D, et al: The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-574, 2011